Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial

What the coverage shows

NBC News and CNN both lead on the personalized mRNA melanoma vaccine and the shared 42% figure, so their coverage converges on the trial result itself. NBC News adds that the vaccine reduced the risk of recurrence and death compared with standard treatment, while CNN frames the finding as opening a door to a new way to treat cancer.

Written by Crossfiled from the 2 headlines and extracts below, not from the articles themselves. It describes how the outlets framed this, not what happened. Open any headline for a summary of that article.